Abstract

Provided are a BDCA2-targeting antibody or antigen-binding fragment thereof, and a use thereof, relating to the technical field of biology. The antibody or antigen-binding fragment thereof comprises: a heavy chain complementarity determining region (HCDR), the HCDR including at least one selected from SEQ ID NOs: 1-12, or an amino acid sequence having at least 80% homology therewith. The provided antibody or antigen-binding fragment thereof can bind to human and monkey BDCA2, effectively blocking the release of IFN-α by pDCs, and has advantages such as high specificity, affinity and solubility. A drug prepared on the basis of the antibody or antigen-binding fragment thereof can be used for effectively treating diseases associated with pDC and IFN-α abnormalities, such as autoimmune diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 15/13 - Immunoglobulins
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 37/02 - Immunomodulators
• A61P 17/00 - Drugs for dermatological disorders

Goods & Services

Shampoos; laundry preparations; facial cleansing milk; cleaning preparations; cosmetics; collagen preparations for cosmetic purposes; make-up; serums for cosmetic purposes; beauty masks; cosmetics for animals. Esthetic massage apparatus; medical apparatus and instruments; massage apparatus; therapeutic facial masks; eye massage apparatus; LED masks for therapeutic purposes; LED facial aesthetic treatment apparatus; lasers for beauty therapy; facial aesthetic treatment apparatus using ultrasonic waves.

Goods & Services

Shampoos; laundry preparations, namely, laundry detergent; facial cleansing milk; cleaning preparations; cosmetics; collagen preparations for cosmetic purposes; make-up; serums for cosmetic purposes; beauty masks; cosmetics for animals. Esthetic massage apparatus, namely, electric esthetic massage apparatus for household purposes; medical apparatus and instruments, namely, surgical apparatus and instruments for medical use; massage apparatus; therapeutic facial masks; massage apparatus for eyes; LED masks for therapeutic purposes; LED facial aesthetic treatment apparatus, namely, apparatus using a light emitting diode for performing aesthetic facial treatment procedures; lasers for beauty therapy, namely, lasers for the cosmetic treatment of the face and skin; facial aesthetic treatment apparatus using ultrasonic waves, namely, cosmetic apparatus using ultrasonic waves for performing aesthetic facial treatment procedures.

Abstract

An Fc mutant and a heterodimeric Fc fusion protein. The Fc mutant comprises: a first peptide segment, compared with an Fc fragment of wild-type IgG1, the first peptide segment having the following mutations: positions 366 and 354, and at least one of positions 351, 368, 392, 405, and/or 409; and a second peptide segment, compared with the Fc fragment of wild-type IgG1, the second peptide segment having the following mutations: at least one of positions 349, 351, 366, 368, 399, and/or 407, wherein the first peptide segment and the second peptide segment are connected. The fusion protein comprises the Fc mutant described above.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• A61K 38/25 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

The present invention relates to a composition comprising a growth hormone fusion protein and a use thereof. The composition comprises: the growth hormone fusion protein and at least one of a buffering agent and a protective agent; a use of the described composition in the preparation of a drug for the treatment and/or prevention of growth hormone abnormality-related diseases.

IPC Classes  ?

• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

Provided are an Fc fragment mutant, a fusion protein, a nucleic acid molecule, an expression vector, a recombinant cell, a pharmaceutical composition and use thereof, and a method for preventing and/or treating a disease associated with abnormal growth hormone. The Fc fragment mutant has an amino acid sequence as shown in any one of SEQ ID NOs: 2 to 5; the fusion protein comprises: a second peptide comprising a bioactive molecular functional region, and a third peptide connected with the second peptide, the third peptide comprising an Fc fragment mutant according to any one of the above-mentioned Fc fragment mutant.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Provided are an Fc fragment mutant, a fusion protein, a nucleic acid molecule, an expression vector, a recombinant cell, pharmaceutical composition and use thereof, and a method for preventing or treating a disease associated with abnormal growth hormone. The Fc fragmentmutant has an amino acid sequence as shown in any one of SEQ ID NOs: 2 to 7; the fusion protein comprises: asecond peptide comprising a bioactive molecular functional region, and a third peptide connected with the second peptide, the third peptide comprising an Fc fragment mutant according to any one of the above-mentioned Fc fragment mutant.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided herein are a growth hormone fusion protein and its use thereof. The fusion protein comprises an Fc mutant, wherein the Fc mutant comprises the first peptide chain, wherein the first peptide chain 1) comprises mutantions at the following positions in comparision to a wild-type IgG4 Fc fragment: at least one of amino acid in positions 234, 235, 298, 299, and 300; Or positions 231-239; Or 2) comprising mutantions at the following positions in comparision to a wild-type IgG1 Fc fragment: positions 228-239, and/or, at least one of amino acid in positions 268, 296, 330 and 331.

IPC Classes  ?

• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 19/00 - Hybrid peptides
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12N 15/18 - Growth hormones
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells